Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Bringing a prophylactic Ebola vaccine to licensure

Obiettivo

The overall aim of EBOVAC3 is to support an essential part of remaining clinical and manufacturing activities required for licensure in the European Union (EU) and the United States (US) of a candidate heterologous prime-boost prophylactic vaccine regimen against Ebola virus disease that is under development at Janssen Vaccines & Prevention B.V. The intended target indication is defined as:

“A prime-boost regimen with Ad26.ZEBOV as prime vaccine and MVA-BN®-Filo as boost vaccine indicated for the prevention of Ebola virus disease (EVD) caused by EBOV of the Zaire ebolavirus species in adults and elderly (aged ≥65 years), human immunodeficiency virus (HIV)-infected adults, and children aged ≥1 year.”

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

RIA - Research and Innovation action

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) H2020-JTI-IMI2-2015-08-single-stage

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL CHARTER
Contributo netto dell'UE
€ 12 162 503,75
Indirizzo
KEPPEL STREET
WC1E 7HT London
Regno Unito
Regione
London Inner London — West Camden and City of London
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
€ 12 162 503,75

Partecipanti (9)